Amarantus Subsidiary MANF Therapeutics Announces Patent Issuances in Europe and China Covering MANF as a Treatment and Biomar...
January 03 2018 - 8:00AM
InvestorsHub NewsWire
Amarantus
Subsidiary MANF Therapeutics
Announces Patent
Issuances in Europe and
China Covering MANF
as a Treatment and Biomarker in
Diabetes and Publication of MANF
Human Pre-Diabetes and
Diabetes Biomarker Data
- Patents extend MANF Therapeutics' exclusivity for use of
MANF as a treatment and a biomarker for beta cell
disorders in Europe and China
into 2032
- List of diseases covered by patents
include Type-1 diabetes, Type-2
diabetes and Wolfram's Syndrome
- Publication opens potential to diagnose and monitor
pre-diabetes and diabetes patients
SAN FRANCISCO, CA -- January 3,
2018 -- InvestorsHub NewsWire -- Amarantus Bioscience
Holdings, Inc. (OTCPK:
AMBS), a US-based biotechnology
holding
company
with
wholly-owned subsidiaries developing
first-in-class orphan
neurologic, regenerative medicine
and
ophthalmic therapies, today announced that its wholly-owned subsidiary
MANF Therapeutics, Inc. was issued
patents in
Europe and
China entitled "Beta Cell
Disorders" covering the therapeutic and biomarker
use of
mesencephalic
astrocyte-derived neurotrophic factor (MANF) in beta cell disorders, including
pre-diabetes, Type-1 diabetes, Type-2 diabetes and
Wolfram's
Syndrome. The patents extend exclusivity for
the therapeutic and
biomarker use of MANF in Europe
and China
into
2032.
Additionally,
the Company announced the publication of a peer-reviewed
article
in Endocrine
Journal entitled "Circulating mesencephalic
astrocyte-derived neurotrophic factor is increased in newly
diagnosed prediabetic and diabetic patients, and is associated with
insulin resistance" describing how
a
MANF-based ELISA was used to identify levels of
circulating
MANF
protein
in pre-diabetes and
diabetes patients. Results from these tests
demonstrated that blood levels of MANF
were correlated with insulin
sensitivity indices in pre-diabetes patients in
the 257 participant study. The authors of
the publication concluded that
MANF
serum
levels were higher in patients with newly
diagnosed pre-diabetes and
type-2
diabetes than in non-glucose tolerant
controls, and that MANF appears to be associated
with the Matsuda Index, QUICKI and
HOMA-IR in pre-diabetes patients.
About Amarantus Bioscience
Holdings, Inc.
Amarantus Bioscience Holdings (AMBS)
is a biotechnology company developing treatments and diagnostics
for diseases in the areas of neurology, regenerative medicine and
orphan diseases through its
subsidiaries. AMBS' wholly-owned
subsidiary Elto Pharma, Inc. has development rights to
eltoprazine, a Phase 2b-ready small molecule indicated for
Parkinson's disease levodopa-induced dyskinesia,
Alzheimer's
aggression and adult ADHD. AMBS acquired the rights to the
Engineered Skin Substitute program (ESS), a regenerative
medicine-based approach for treating severe burns with
full-thickness autologous skin grown in tissue culture
that is being
pursued by AMBS' wholly-owned subsidiary
Cutanogen Corporation. AMBS' wholly-owned subsidiary
MANF Therapeutics, Inc. owns key intellectual property
rights and
licenses from a number of prominent universities related to the
development of the therapeutic protein known as
mesencephalic astrocyte-derived neurotrophic factor
(MANF). MANF Therapeutics, Inc. is developing MANF-based
products as treatments for brain and ophthalmic
disorders.
MANF was discovered by the Company's Chief Scientific Officer John
Commissiong, PhD. Dr. Commissiong
discovered MANF from AMBS' proprietary discovery
engine PhenoGuard. AMBS also owns approximately
80 million shares
of Avant Diagnostics, Inc. via the sale of its wholly-owned
subsidiary Amarantus Diagnostics, Inc.
that occurred in
May 2016.
For further information please
visit www.Amarantus.com, or connect with the
Amarantus
on Facebook, LinkedIn, Twitter and Google+.
About MANF
Therapeutics, Inc.
MANF
(mesencephalic-astrocyte-derived neurotrophic factor) is believed
to have broad potential because it is a naturally-occurring protein
produced by the body to reduce/prevent
apoptosis (cell
death) in response to injury or disease, via the unfolded protein
response. By administering exogenously produced
MANF the
body, Amarantus is seeking to use a
regenerative medicine approach to assist the body with higher
quantities of MANF when needed. Amarantus is the front-runner and primary
holder of intellectual property around MANF, and is initially
focusing on the development of MANF-based protein
therapeutics.
In April 2017,
Amarantus
incorporated the
wholly-owned subsidiary MANF Therapeutics, Inc. to focus on the
preclinical and clinical development of MANF. MANF's lead indication is
retinitis pigmentosa, and additional indications including
Parkinson's disease, diabetes and Wolfram's syndrome are
envisioned. Further applications for MANF
may include Alzheimer's disease, traumatic brain injury, myocardial
infarction, antibiotic-induced ototoxicity and certain
other orphan
diseases.
Forward-Looking
Statements
Certain statements, other than
purely historical information, including estimates, projections,
statements relating to our business plans, objectives, and expected
operating results, and the assumptions upon which those statements
are based, are forward-looking statements. These forward-looking
statements generally are identified by the words "believes,"
"project," "expects," "anticipates," "estimates," "intends,"
"strategy," "plan," "may," "will," "would," "will be," "will
continue," "will likely result," and similar expressions.
Forward-looking statements are based on current expectations and
assumptions that are subject to risks and uncertainties which may
cause actual results to differ materially from the forward-looking
statements. Our ability to predict results or the actual effect of
future plans or strategies is inherently uncertain. Factors which
could have a material adverse effect on our operations and future
prospects on a consolidated basis include, but are not limited to:
changes in economic conditions, legislative/regulatory changes,
availability of capital, interest rates, competition, and generally
accepted accounting principles. These risks and uncertainties
should also be considered in evaluating forward-looking statements
and undue reliance should not be placed on such
statements.
Amarantus
Investor and Media Contact:
Ascendant Partners,
LLC
Richard Galterio
+1-732-410-9810
rich@ascendantpartnersllc.com
Source: Amarantus Bioscience Holdings,
Inc.
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Apr 2024 to May 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From May 2023 to May 2024